Evidence map›Paper›PMID 33910636›Full record

ArticleTranslational neurodegeneration2021

Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson's disease: implication of acrolein and TRPA1.

Liangqin Shi, Yazhou Lin, Yucheng Jiao, Seth A Herr, Jonathan Tang, Edmond Rogers, Zhengli Chen, Riyi Shi

Open access · goldAbstract read
In one paragraph

Article in Translational neurodegeneration, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. TRPA1 Role in Inflammatory Disorders: What Is Known So Far?International journal of molecular sciences · 2022
    Review
  20. A high-affinity cocaine binding site associated with the brain acid soluble protein 1.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Liangqin ShiCollege of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
Yazhou LinCenter for Paralysis Research & Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA.
Yucheng JiaoCenter for Paralysis Research & Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA.
Seth A HerrCenter for Paralysis Research & Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA.
Jonathan TangCenter for Paralysis Research & Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA.
Edmond RogersCenter for Paralysis Research & Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA.
Zhengli ChenLaboratory of Animal Disease Model, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 625014, China. chzhli75@163.com.
Riyi ShiCenter for Paralysis Research & Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA. riyi@purdue.edu.ORCID 0000-0002-7297-9428
Purdue University West Lafayette · USSichuan Agricultural University · CN

Funding

Biomechanics of Blast InjuryR21NS090244 · NINDS · PURDUE UNIVERSITY · PI SHI, RIYI · 2014 to 2015
$426k
A novel enzymatic mechanism for removing neurotoxic aldehydes after rodent spinal cord injuryR21NS115094 · NINDS · PURDUE UNIVERSITY · PI SHI, RIYI · 2019 to 2020
$424k
NINDS NIH HHS R21 NS090244NINDS NIH HHS R21 NS115094
6 · The paper itself

Abstract

backgroundThe mechanisms underlying lesions of dopaminergic (DA) neurons, an essential pathology of Parkinson's disease (PD), are largely unknown, although oxidative stress is recognized as a key factor. We have previously shown that the pro-oxidative aldehyde acrolein is a critical factor in PD pathology, and that acrolein scavenger hydralazine can reduce the elevated acrolein, mitigate DA neuron death, and alleviate motor deficits in a 6-hydroxydopamine (6-OHDA) rat model. As such, we hypothesize that a structurally distinct acrolein scavenger, dimercaprol (DP), can also offer neuroprotection and behavioral benefits.

methodsDP was used to lower the elevated levels of acrolein in the basal ganglia of 6-OHDA rats. The acrolein levels and related pathologies were measured by immunohistochemistry. Locomotor and behavioral effects of 6-OHDA injections and DP treatment were examined using the open field test and rotarod test. Pain was assessed using mechanical allodynia, cold hypersensitivity, and plantar tests. Finally, the effects of DP were assessed in vitro on SK-N-SH dopaminergic cells exposed to acrolein.

resultsDP reduced acrolein and reversed the upregulation of pain-sensing transient receptor potential ankyrin 1 (TRPA1) channels in the substantia nigra, striatum, and cortex. DP also mitigated both motor and sensory deficits typical of PD. In addition, DP lowered acrolein and protected DA-like cells in vitro. Acrolein's ability to upregulate TRPA1 was also verified in vitro using cell lines.

conclusionsThese results further elucidated the acrolein-mediated pathogenesis and reinforced the critical role of acrolein in PD while providing strong arguments for anti-acrolein treatments as a novel and feasible strategy to combat neurodegeneration in PD. Considering the extensive involvement of acrolein in various nervous system illnesses and beyond, anti-acrolein strategies may have wide applications and broad impacts on human health.

Indexed as

AcroleinAnimalsBehavior, AnimalCerebral CortexDimercaprolDopaminergic NeuronsHydroxydopaminesMaleMotor ActivityNeostriatumNeuroprotective AgentsPainPain MeasurementParkinson Disease, SecondaryRatsRats, Sprague-DawleyAcroleinDimercaprolHydroxydopaminesNeuroprotective AgentsTRPA1 Cation ChannelTrpa1 protein, ratAcroleinDimercaprolNeuroinflammationOxidative stressParkinson’s diseaseTRPA1

Identifiers

PMID33910636
PMCPMC8080346
OpenAlexW3158857568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.